If you are experiencing serious side effects from a medication or an injury from a defective product you should first speak with your doctor. Then contact Brent M. Cordell for a free initial consultation and case evaluation. Our attorneys also represent family members of those who died a wrongful death due to dangerous drugs or defective products.
Brent M. Cordell,
Attorney at Law
1445 North Loop West,
Suite 700 Houston, TX.77008
Voice: (713) 248-5265
email: bcordelllaw@gmail.com
The Actiq fentanyl lollipop is a narcotic pain medication which is only intended for treatment of break through cancer pain in patients who are already opioid tolerant. As a result of aggressive promotion and advertisement by the manufacturer, Cephalon, Inc., the Actiq lollipop has been widely prescribed to individuals who never should have received the drug.There have been hundreds of reports of overdose and death as a resolve the fentanyl lollipops.
The candy-like method used for the powerful fentanyl delivery combined with widespread prescription for non-approved uses has resulted in serious and potentially fatal injuries. The medication has also been abused, resulting in death for many users. There have also been reports of children dying after they mistook the powerful narcotic for candy.
ACTIQ (fentanyl citrate)®
Actiq (fentanyl citrate) is an extremely powerful narcotic which is delivered in the form of a lollipop by placing the drug in a lozenge on the end of a stick.
When the narcotic lollipop is placed against the cheek of the mouth and sucked on, the medication is delivered directly into the blood stream. It usually provides relief of even the most severe pain within 15 minutes. The FDA approved Actiq in November 1998 for treatment in cancer patients suffering pain which could not be relieved by other medications.
Although it has only been approved for use by cancer patients, the manufacturer negligently allowed the medication to be prescribed to treat less serious ailments, such as chronic back pain, knee pain and head aches. It has been estimated that over 80% of Actiq users do not have cancer, and there have been allegations the sales representatives actively promoted the drug for non-cancer uses.